Table 2.
Quality assessment of included studies
|
Random Sequence Generation |
Allocation Concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | |
|---|---|---|---|---|---|---|
| ATTRACTION‐2, Kang 2017 18 , 19 | Low | Unclear | Low | Low | Low | Low |
| JAVELIN gastric 300, Bang 2018 20 | Low | Low | Low | Low | Unclear | Low |
| KEYNOTE 061, Shitra 2018 16 | Low | Low | Unclear | Low | Unclear | Low |
| KEYNOTE 062, Shitara 2019 17 , 21 , a | Unclear | Unclear | Unclear | Low | Low | Unclear |
| JAVELIN gastric 100, Moehler 2020 22 , a | Unclear | Unclear | Low | Low | Unclear | Unclear |
a
As the KEYNOTE 062 have and the JAVELIN gastric studies have been presented only in a form of abstracts/ oral presentations and the full manuscripts have been published yet, data for quality assessment are limited.